EyeSense GmbH

EyeSense is a new, innovative, start-up company. It is a spin-off of Novartis - with strong investors and great perspectives primarily in the large diabetes market which is constantly growing worldwide.

With more than 220 million diabetics in the world today, blood glucose measurement (BGM) is one of the biggest diagnostics markets. BGM is estimated to achieve annual sales of 8 billion US Dollars by 2007 and is one of the most relevant tools to prevent severe damage to the patient’s health such as cardio-vascular diseases, kidney failure or blindness. If measured regularly and accurately the measurement of glucose levels can therefore help to save health-insurance systems billions of dollars by simultaneously improving patients’ quality of life significantly.

EyeSense has the goal of making BGM easier and painless, based on a highly innovative product concept: an ophthalmic diagnostics system which can measure glucose levels without sampling blood each time, solely via a non-invasive sensor technology.

EyeSense is still in the research and development phase, but has already gained promising data with first patient studies and achieved all project milestones set by the investors. It is planned to launch the new BGM device in 2013.

Basically the innovative concept offers completely new ways of self-diagnosis applicable to other areas too. Overall the technology can be seen as a great step forward in this field.